Frontier BioStrategy Managing Director, Commercial, Ben Cicora joined AgriBusiness Global’s Sustainable Podcast to discuss why biological technology companies stall short of commercial scale, and what separates the ones that don’t.
In an episode published July 23, 2026, host Sarah Webb of AgriBusiness Global spoke with Ben Cicora, Managing Director, Commercial at Frontier BioStrategy, about the pitfalls that surface repeatedly among early-stage biological technology companies and the disciplines that distinguish those that reach commercial scale.
Cicora identified the regulatory environment as the most consistently underestimated variable. Companies that treat registration as a downstream formality tend to discover the cost late, in the form of delayed approvals, narrower label claims, and a considerably harder path into additional jurisdictions. The remedy is not more regulatory work. It is sequencing: regulatory strategy, commercial strategy, and R&D developed in parallel rather than in series.
He pointed to two further patterns that drain early-stage capital. The first is market overreach, where companies pursue several markets at once and gain durable traction in none. The second is deferring manufacturing process development, which compresses margins early and weakens a company’s negotiating position with strategic partners across geographies.
On customer engagement, Cicora’s recommendation was to start before the first pitch. Conversations with growers, PCAs, industry influencers, and founders who have already been through a commercial launch sharpen internal focus, strengthen the investor narrative, and align the team around a clearly defined end customer and problem.
The ones that are successful are ruthless when it comes to focus.
Ben Cicora, Managing Director, Commercial, Frontier BioStrategy
Asked where the biologicals sector still has ground to make up, Cicora noted that a number of companies continue to position themselves as everything to the grower, which dilutes the message. Three decades of preconceived notions about biological performance have produced a durable “show me, prove it” posture at the grower level. His guidance: be honest about what the business does well, and deliver on it.
Listen to the Full Episode
Sustainable Podcast: Ben Cicora of Frontier BioStrategy on What Differentiates Successful Bio Companies — AgriBusiness Global, July 23, 2026.
Working on something that touches these topics?
Most engagements begin with a 30-minute scoping conversation.